clinical trial · NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Non-Small Cell Lung CancerIvonescimab InjectionPembrolizumab Injection
brief summary
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
started
Feb 27, 2025
primary completion
Apr 1, 2028
completion
Jun 1, 2029
last updated
Feb 24, 2026
official title
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol